Get access to our best features
Get Started
Subscribe
Israeli-Palestinian Conflict
US Politics
2024 US Election
Donald Trump
US Social Issues
Joe Biden
US Crime
Baseball
Republican Party
US Economy
NFL
Earth Day
US Immigration
Get access to our best features
Get Started
Published 2 years ago

SII seeks permission for Phase-3 trial of Covovax as booster dose in children aged 2 to 18 years

Summary by Tribune India
The Serum Institute of India (SII) has sought permission from the country's drug regulator to conduct Phase-3 trial to evaluate the safety and immunogenicity of its COVID-19 vaccine Covovax as a booster dose in children aged two to 18 years, official sources said on Sunday.

0 Articles

All
Left
Center
Right
Times of IndiaTimes of India

SII seeks permission for Phase-3 trial of Covovax as booster dose in children aged 2 to 18 years

In an application, SII Director for Government and Regulatory Affairs Prakash Kumar Singh has sought permission to conduct the Phase-3, observer-blinded, randomised, controlled study in children aged two to 18 years in India who have already received primary vaccination against COVID-19 with Covovax at least six months ago.

2 years ago·India
Read Full Article
News18 IndiaNews18 India

SII Seeks Permission for Phase-3 Trial of Covovax as Booster Dose in Children Aged 2 to 18 Years

India began administering precaution doses of Covid-19 vaccines to all aged above 18 years at private vaccination centres from April 10

2 years ago·India
Read Full Article
Business StandardBusiness Standard

SII seeks permission for trial of Covovax as booster for ages 2 to18 yrs

SII has sought permission from country's drug regulator to conduct Phase-3 trial to evaluate safety and immunogenicity of its COVID vaccine Covovax as a booster dose in children aged two to 18 years

2 years ago·India
Read Full Article
Firstpost NewsFirstpost News

SII seeks permission for next trial of Covovax as booster dose in children aged 2 to 18 years-India News , Firstpost

The Drugs Controller General of India (DCGI) had granted permission in March for conducting Phase-3 clinical trial of Covovax as a booster dose in adults

2 years ago·Mumbai, India
Read Full Article
Deccan HeraldDeccan Herald

SII seeks permission for Phase-3 Covovax booster trial in 2-18 age group

The Serum Institute of India (SII) has sought permission from the country's drug regulator to conduct Phase-3 trial to evaluate the safety and immunogenicity of its Covid-19 vaccine Covovax as a booster dose in children aged two to 18 years, official sources said on Sunday. The Drugs Controller General of India (DCGI) had granted permission in March for conducting Phase-3 clinical trial of Covovax as a booster dose in adults.

2 years ago
Read Full Article
Tribune IndiaTribune India

SII seeks permission for Phase-3 trial of Covovax as booster dose in children aged 2 to 18 years

The Serum Institute of India (SII) has sought permission from the country's drug regulator to conduct Phase-3 trial to evaluate the safety and immunogenicity of its COVID-19 vaccine Covovax as a booster dose in children aged two to 18 years, official sources said on Sunday.

2 years ago·Chandigarh, India
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 83% of the sources lean Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

AsiaAsia
HealthHealth
VaccinesVaccines
CoronavirusCoronavirus
MedicalMedical
New DelhiNew Delhi
Trending Topics
Ground News logo
US
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble Newsletter
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc.
News
For You
Search
BlindspotLocal